Chemotherapy is a type of systemic anti-cancer therapy (SACT). Chemotherapy information sheets provide details about individual chemotherapy treatments.
We also have a number of immunotherapy information sheets. Immunotherapy is a treatment which uses your immune system to fight cancer. It works by helping the immune system recognise and attack cancer cells. Some types of immunotherapy are also called targeted treatments or biological therapies.
Your doctor will discuss your treatment with you when you come to The Christie.
Each information sheet includes:
- name of drugs
- the way the drugs are given, for example, injection or via a drip
- treatment cycle (which days or weeks you have treatment and how long treatment lasts)
- side effects and how to cope
- contact numbers
Click on the name of the treatment you wish to view.
A
Alpelisib [PDF, 103 KB]
You can also read this information in an accessible format on our Alpelisib page.
Anastrozole [PDF, 164 KB]
You can also read this information in an accessible format on our Anastrozole page.
Atezolizumab and nab-paclitaxel [PDF, 104 KB]
You can also read this information in an accessible format on our Atezolizumab and nab-paclitaxel page.
B
C
Capecitabine (breast) [PDF, 103 KB]
You can also read this information in an accessible format on our Capecitabine (breast) page.
Carboplatin for breast patients [PDF, 103 KB]
You can also read this information in an accessible format on our Carboplatin (breast) page.
Cyclophosphamide, methotrexate and fluorouracil (CMF) [PDF, 104 KB]
You can also read this information in an accessible format on our Cyclophosphamide, methotrexate and fluorouracil (CMF) page.
Cemiplimab (Libtayo®) - for gynaecological cancer
You can also read this information in an accessible format on our Cemiplimab (Libtayo®) - for gynaecological cancer page.
D
Docetaxel [PDF, 104 KB]
You can also read this information in an accessible format on our Docetaxel page.
Docetaxel, carboplatin, pertuzumab and trastuzumab (TCarboPH) [PDF, 104 KB]
You can also read this information in an accessible format on our Docetaxel, carboplatin, pertuzumab and trastuzumab (TCarboPH) page.
Docetaxel and cyclophosphamide [PDF, 104 KB]
You can also read this information in an accessible format on our Docetaxel and cyclophosphamide (TC) page.
Docetaxel, carboplatin, and trastuzumab (TCarboH) [PDF, 104 KB]
You can also read this information in an accessible format on our Docetaxel, carboplatin, and trastuzumab (TCarboH) page.
Docetaxel, pertuzumab and trastuzumab (TPH) [PDF, 104 KB]
You can also read this information in an accessible format on our Docetaxel, pertuzumab and trastuzumab (TPH) page.
Doxorubicin and cyclophosphamide [PDF, 104 KB]
You can also read this information in an accessible format on our Doxorubicin and cyclophosphamide (AC) page.
E
Epirubicin [PDF, 103 KB]
You can also read this information in an accessible format on our Epirubicin page.
Epirubicin and cyclophosphamide [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin and cyclophosphamide (EC) page.
Epirubicin then cyclophosphamide then docetaxel, trastuzumab (EC-TH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin then cyclophosphamide then docetaxel, trastuzumab (EC-TH) page.
Epirubicin then cyclophosphamide, methotrexate and fluorouracil (Epi-CMF) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin then cyclophosphamide, methotrexate and fluorouracil (Epi-CMF) page.
Epirubicin, cyclophosphamide then docetaxel (EC-T) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then docetaxel (EC-T) page.
Epirubicin, cyclophosphamide then docetaxel, pertuzumab and trastuzumab (EC-TPH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then docetaxel, pertuzumab and trastuzumab (EC-TPH) page.
Epirubicin, cyclophosphamide then docetaxel, trastuzumab (EC-TH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then docetaxel, trastuzumab (EC-TH) page.
Epirubicin, cyclophosphamide then paclitaxel (EC-P or P-EC) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin-cyclophosphamide then paclitaxel (EC-P or P-EC) page.
Epirubicin, cyclophosphamide then paclitaxel and trastuzumab (EC-PH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then paclitaxel and trastuzumab (EC-PH) page.
Epirubicin, cyclophosphamide then paclitaxel, pertuzumab and trastuzumab (EC-PPH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then paclitaxel, pertuzumab and trastuzumab (EC-PPH) page.
Epirubicin-cyclophosphamide then carboplatin-paclitaxel (EC-PC) or (PC-EC) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin-cyclophosphamide then carboplatin-paclitaxel (EC-PC) or (PC-EC) page.
Eribulin [PDF, 103 KB]
You can also read this information in an accessible format on our Eribulin page.
Everolimus (Breast) [PDF, 104 KB]
You can also read this information in an accessible format on our Everolimus page.
Exemestane [PDF, 167 KB]
You can also read this information in an accessible format on our Exemestane page.
F
Fulvestrant (Faslodex®) [PDF, 164 KB]
You can also read this information in an accessible format on our Fulvestrant (Faslodex®) page.
G
Gemcitabine and carboplatin (Breast) [PDF, 104 KB]
You can also read this information in an accessible format on our Gemcitabine and carboplatin (breast) page.
Gemcitabine and paclitaxel [PDF, 104 KB]
You can also read this information in an accessible format on our Gemcitabine and paclitaxel page.
Glofitamab, gemcitabine and oxaliplatin [PDF, 98 KB]
You can also read this information in an accessible format on our Glofitamab, gemcitabine and oxaliplatin page.
H
High dose melphalan conditioning for autologous transplant (inpatient) [PDF, 170 KB]
Before you can receive your transplant, your bone marrow and immune system need to be prepared to make way for the new cells. This is called conditioning. Your new cells will be scheduled for reinfusion into you the day after the conditioning therapy has finished.
I
Ibandronic acid for metastatic breast cancer [PDF, 167 KB]
You can also read this information in an accessible format on our Ibandronic acid for breast cancer page.
L
Letrozole [PDF, 170 KB]
You can also read this information in an accessible format on our Letrozole page.
M
Mitomycin, methotrexate and mitoxantrone (MMM) [PDF, 104 KB]
You can also read this information in an accessible format on our Mitomycin, methotrexate and mitoxantrone (MMM) page.
N
Nab-paclitaxel (albumin bound) [PDF, 104 KB]
You can also read this information in an accessible format on our Nab-paclitaxel (albumin bound) page.
Nab-paclitaxel (albumin-bound) and carboplatin [PDF, 104 KB]
You can also read this information in an accessible format on our Nab-paclitaxel (albumin-bound) and carboplatin page.
Neratinib [PDF, 103 KB]
You can also read this information in an accessible format on our Neratinib page.
Niraparib (Zejula®) [PDF, 101 KB]
Niraparib (Zejula®) is a systemic anti-cancer therapy. This group of drugs targets and interferes with the processes in the cells that cause cancer to grow.
O
Obinutuzumab (lymphoma) [PDF, 86KB]
You can also read this information in an accessible format on our Obinutuzumab (lymphoma) page.
P
Paclitaxel [PDF, 103 KB]
You can also read this information in an accessible format on our Paclitaxel page.
Paclitaxel and trastuzumab (PH) [PDF, 104 KB]
You can also read this information in an accessible format on our Paclitaxel and trastuzumab (PH) page.
Palbociclib [PDF, 103 KB]
You can also read this information in an accessible format on our Palbociclib page.
Pembrolizumab and lenvatinib (Lenvima®) [PDF, 172 KB]
Pembrolizumab is a type of anti-cancer treatment called immunotherapy. Lenvatinib (Lenvima®) is a systemic anticancer therapy. This group of drugs stops cancer cells from growing.
Pembrolizumab with nab-paclitaxel (Abraxane) or paclitaxel [PDF, 104 KB]
You can also read this information in an accessible format on our Pembrolizumab with nab-paclitaxel or paclitaxel page.
Pembrolizumab with paclitaxel and carboplatin followed by epirubicin and cyclophosphamide (Pembro/PC-EC) [PDF, 104 KB]
You can also read this information in an accessible format on our Pembrolizumab with paclitaxel and carboplatin followed by epirubicin and cyclophosphamide (Pembro/PC-EC) page.
R
Ribociclib [PDF, 103 KB]
You can also read this information in an accessible format on our Ribociclib page.
S
Sacituzumab govitecan [PDF, 169 KB]
You can also read this information in an accessible format on our Sacituzumab govitecan page.
Systemic anti-cancer treatment (SACT): A guide for patients and their carers (previously called chemotherapy) [PDF, 1,017 KB]
Previously the 'Chemotherapy: A guide for patients and their carers' booklet. You can also read this information in an accessible format on our Systemic anti-cancer therapy (SACT) website section.
T
Trastuzumab deruxtecan (Enhertu®) [PDF, 103 KB]
You can also read this information in an accessible format on our Trastuzumab deruxtecan (Enhertu®) page.
Trastuzumab emtansine (Kadcyla®) [PDF, 104 KB]
You can also read this information in an accessible format on our Trastuzumab emtansine (Kadcyla®) page.
Tucatinib, capecitabine and trastuzumab [PDF, 104 KB]
You can also read this information in an accessible format on our Tucatinib, capecitabine and trastuzumab page.
U
V
Vinorelbine (oral) [PDF, 103 KB]
You can also read this information in an accessible format on our Vinorelbine (oral) page.
Vinorelbine and capecitabine [PDF, 104 KB]
You can also read this information in an accessible format on our Vinorelbine and capecitabine page.